Vytorin (correction)
Executive Summary
Print DTC ads emphasizing the ability of Merck/Schering-Plough's Vytorin to reduce LDL-cholesterol levels began running on March 30. Following an FDA request in January, the ads carry the disclaimer that "Vytorin has not been shown to reduce heart attacks or strokes more than Zocor alone." A recent article mistakenly said the statement is being included in DTC ads as a result of safety signals identified in the ENHANCE trial (1"The Pink Sheet," April 14, 2008, In Brief). Furthermore, no new safety signals were associated with Vytorin treatment in the ENHANCE trial